{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Oncology Times: January 2012
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Purpose of Activity
To provide registered professional nurses with the latest information about treatment options for melanoma and ovarian cancer.Learning Objectives
After completing this continuing education activity you will be able to:
- Compare and contrast the first-line drug therapies for treating melanoma.
- Summarize the benefits and drawbacks to using bevacizumab to treat ovarian cancer.
- Outline the information presented here about inhibiting angiogenesis in ovarian cancer.
Disclosures
The author and planners have disclosed that they have no financial relationships related to this article.
Price:
$21.95
Credits:
- ANCC 2.4 CH
- DC - BON 2.4 CH
- KY-BON 2.4 CH
Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.--------------------------------------------------This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia and Florida #50-1223. Your certificate is valid in all states.--------------------------------------------------The ANCC's accreditation status of Lippincott Williams & Wilkins Department of Continuing Education refers only to its continuing nursing educational activities and does not imply Commission on Accreditation approval or endorsement of any commercial product.
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Test Code: OT0112
Published: January 10 2012
Expires: 12/31/2026
Sources:
Oncology Times
Required Passing Score: 11/15 (73%)
Specialties:
Oncology
Topics:
Melanoma